“…), which circulate via the portal and systemic vascular system to other insulin target tissues (liver, muscle and islet cells) and induce insulin resistance (Kahn & Flier 2000, Steppan et al 2001, Wellen & Hotamisligil 2003, Lau et al 2005. Excess saturated free fatty acids (FFAs) such as palmitate activate inflammation and induce insulin resistance via multiple mechanisms including, but not limited to, serine phosphorylation of insulin receptor substrate-1 (IRS-1) and up-regulation of suppressors of cytokine signaling (SOCS; Paz et al 1997, Lin et al 2000, Emanuelli et al 2001, Perreault & Marette 2001, Aguirre et al 2002, Chavez et al 2003, Furukawa et al 2004, Ajuwon & Spurlock 2005, Boden et al 2005, Hotamisligil 2005, Jove et al 2005, Khamzina et al 2005, Shi et al 2006, Solinas et al 2006, Nakamura et al 2009, Ragheb et al 2009). Therefore, agents capable of blocking FFA-mediated inflammation and insulin resistance may be useful as novel therapeutics for the treatment of T2DM.…”